Audalis 18 mg Norveç - Norveççe - Statens legemiddelverk

audalis 18 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 18 mg

Audalis 25 mg Norveç - Norveççe - Statens legemiddelverk

audalis 25 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 25 mg

Audalis 40 mg Norveç - Norveççe - Statens legemiddelverk

audalis 40 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 40 mg

Audalis 80 mg Norveç - Norveççe - Statens legemiddelverk

audalis 80 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 80 mg

Audalis 100 mg Norveç - Norveççe - Statens legemiddelverk

audalis 100 mg

medice arzneimittel pütter gmbh & co kg - atomoksetinhydroklorid - tablett, filmdrasjert - 100 mg

Doxorubicin Ebewe 2 mg/ ml Norveç - Norveççe - Statens legemiddelverk

doxorubicin ebewe 2 mg/ ml

ebewe pharma ges.m.b.h nfg. kg - doksorubicinhydroklorid - injeksjonsvæske, oppløsning - 2 mg/ ml

Etoposid Ebewe 20 mg/ ml Norveç - Norveççe - Statens legemiddelverk

etoposid ebewe 20 mg/ ml

ebewe pharma ges.m.b.h nfg. kg - etoposid - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml

Rinvoq Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Xofluza Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

xofluza

roche registration gmbh - baloxavir marboxil - influensa, human - antivirale midler til systemisk bruk - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Nitroglycerin Abcur 1 mg/ ml Norveç - Norveççe - Statens legemiddelverk

nitroglycerin abcur 1 mg/ ml

abcur ab - glyseroltrinitrat - infusjonsvæske, oppløsning - 1 mg/ ml